Solventum Corporation $SOLV Stock: New York Life Investment Management LLC Raises Holdings

New York Life Investment Management LLC increased its holdings in shares of Solventum Corporation (NYSE:SOLV – Free Report) by 39.7% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 41,376 shares of the company’s stock after purchasing an additional 11,759 shares during the period. New York Life Investment Management LLC’s holdings in Solventum were worth $3,647,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of SOLV. North Dakota State Investment Board raised its stake in Solventum by 3.1% in the third quarter. North Dakota State Investment Board now owns 4,525 shares of the company’s stock valued at $399,000 after buying an additional 134 shares during the period. IFP Advisors Inc boosted its position in Solventum by 12.7% during the third quarter. IFP Advisors Inc now owns 1,211 shares of the company’s stock worth $107,000 after purchasing an additional 136 shares during the period. NewEdge Advisors LLC raised its position in shares of Solventum by 2.2% in the first quarter. NewEdge Advisors LLC now owns 6,707 shares of the company’s stock valued at $438,000 after purchasing an additional 144 shares during the period. Clearstead Trust LLC boosted its holdings in shares of Solventum by 61.0% during the 1st quarter. Clearstead Trust LLC now owns 396 shares of the company’s stock worth $26,000 after buying an additional 150 shares during the period. Finally, Diversify Advisory Services LLC grew its stake in Solventum by 3.2% in the 3rd quarter. Diversify Advisory Services LLC now owns 5,000 shares of the company’s stock valued at $439,000 after buying an additional 153 shares during the last quarter.

Solventum Trading Down 0.3%

Shares of SOLV opened at $88.85 on Monday. Solventum Corporation has a fifty-two week low of $62.38 and a fifty-two week high of $94.16. The business has a 50-day moving average of $87.53 and a 200 day moving average of $78.95. The firm has a market cap of $15.08 billion, a P/E ratio of 99.83, a price-to-earnings-growth ratio of 1.27 and a beta of 0.69. The company has a debt-to-equity ratio of 0.99, a quick ratio of 0.72 and a current ratio of 1.03.

Solventum (NYSE:SOLV – Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The company reported $1.45 EPS for the quarter, beating the consensus estimate of $1.34 by $0.11. The business had revenue of $1.95 billion for the quarter, compared to the consensus estimate of $1.93 billion. Solventum had a net margin of 1.91% and a return on equity of 25.03%. The company’s revenue was down 7.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.50 earnings per share. As a group, research analysts forecast that Solventum Corporation will post 7.26 EPS for the current year.

Analyst Upgrades and Downgrades

SOLV has been the topic of a number of analyst reports. Wedbush increased their price target on Solventum from $94.00 to $101.00 and gave the stock an “outperform” rating in a research report on Thursday, August 6th. KeyCorp increased their price target on Solventum from $93.00 to $102.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. Jefferies Financial Group reiterated a “buy” rating on shares of Solventum in a report on Thursday, October 8th. Zacks Research raised Solventum from a “hold” rating to a “strong-buy” rating in a research report on Thursday. Finally, Stifel Nicolaus lifted their price objective on shares of Solventum from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $90.27.

View Our Latest Analysis on Solventum

Solventum Company Profile

(Free Report)

Solventum is a global healthcare company that develops products and services for hospitals, dental professionals, health systems and other care providers. It was formed from 3M’s healthcare business and became an independent public company in April 2024. The company’s offerings include medical and surgical supplies, wound-care products, sterilization and infection-prevention solutions, dental materials and technologies, and software for health information management. Its products and services support clinical care, dental care and healthcare administration.

Recommended Stories

Institutional Ownership by Quarter for Solventum (NYSE:SOLV)

Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.